Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Novartis’ Multiple Sclerosis Pill Slowed Brain Loss in Study

Novartis AG said its Gilenya drug to treat multiple sclerosis helped slow brain loss, a measure linked to the severity of the disease.

Patients taking Gilenya in three large Novartis-led studies lost a third less brain volume than patients taking either a placebo or Biogen Idec Inc.’s Avonex, Novartis said in an e-mailed statement today.

Gilenya was approved in the U.S. in 2010 as the first oral treatment for multiple sclerosis, and cleared for sale in Europe in March 2011. The data may help it beat competition from Sanofi’s oral drug Aubagio, which was brought to market last November, Gordon Francis, who heads Novartis’ clinical science unit for inflammation, said in an interview.

“If I asked you if you’d rather have more brain or less brain, you’d probably say more”, Francis said.

Loss of brain volume is correlated with both the activity and severity of the disease, Francis said.

The results relied on an analysis of data gathered from 3,600 patients with the relapsing form of the disease, and were presented at the annual meeting of the American Academy of Neurology in San Diego.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.